To date 2 multikinase inhibitors (vandetanib and cabozantinib) and 2 RET selective inhibitors (selpercatinib and pralsetinib) have been approved by the Food and Drug Administration (FDA) for the treatment of advanced MTC [30]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.